Showing 2421-2430 of 2652 results for "".
- Long-Term Data Show Value of Intravenous Chemotherapy in Retinoblastomahttps://modernod.com/news/long-term-data-show-value-of-intravenous-chemotherapy-in-retinoblastoma/2477326/Intravenous chemotherapy (IVC), with intra-arterial chemotherapy (IAC) or plaque radiotherapy as needed for globe salvage, can control retinoblastoma without the need for enucleation or external beam radiotherapy (EBRT), 20-year real-world outcomes show, according to a Reuters
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- Study Advances Development of Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/study-advances-development-of-gene-therapy-for-x-linked-retinitis-pigmentosa/2477321/A new study marks a significant advance in developing a gene therapy for X-linked retinitis pigmentosa, a hereditary disease that leads to severe sight loss in young males. Researchers at Bascom Palmer Eye Institute, the Department of Ophthalmology a
- Penn Medicine Study Finds Missing One Eye Appointment Can Lead to Vision Loss in Elderlyhttps://modernod.com/news/penn-medicine-study-finds-missing-one-eye-appointment-can-lead-to-vision-loss-in-elderly/2477319/A Penn Medicine study discovered that missing one ophthalmology appointment within a 2-year period could cause dec
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe
- Market Scope: Miami, Philadelphia, and Virginia Beach in Top 10 Markets of Glaucoma Treatment Opportunityhttps://modernod.com/news/market-scope-miami-philadelphia-and-virginia-beach-in-top-10-markets-of-glaucoma-treatment-opportunity/2477291/The metro areas of New York, Los Angeles, Dallas, and Chicago account for 13 percent of the US glaucoma and ocular hypertension population. However, on a per capita share basis, most of the metro areas in Florida stand out for glaucoma disease, driven largely by the state’s high median age. Naple
- EyeTech Launches EyeOn Ultra-Compact Eye-Tracking Tablet Platformhttps://modernod.com/news/eyetech-launches-eyeon-ultra-compact-eye-tracking-tablet-platform/2477269/EyeTech Digital Systems announced the launch of EyeOn, an all-in-one, ultra-slim eye gaze tablet during this year’s Assistive Technology Industry Association conference in Orlando. The EyeOn eye tracking platform enables people with mobility and motor impairments to select, type, and speak entire
- Glauconix Biosciences Promotes Kimberly Southern to Chief Executive Officerhttps://modernod.com/news/glauconix-biosciences-promotes-kimberly-southern-to-chief-executive-officer/2477262/Glauconix Biosciences announced that its board of directors has appointed Kim Southern as Chief Executive Officer and a member of the Board of Directors effective immediately. Ms. Southern previously held the position of Chief Operating Officer. Since joining the company in May, Ms. Southe
- Study Finds Fewer Than Half of US Clinical Trials Complied With New Regulations on Reporting Resultshttps://modernod.com/news/study-finds-fewer-than-half-of-us-clinical-trials-complied-with-new-regulations-on-reporting-results/2477242/According to research published in The Lancet on Friday, compliance with US regulations requiring clinical trials to report results within 1 year of completion remains poor, with about one